Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

ketamine

AI Biomed Predictions

NRXP – Summer FDA Ketamine Decision Could Reawaken NRXP Speculation

ScanScor Admin / April 13, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

2 weeks ago HOTH – Promising Therapeuti... – This was not a crazy prediction. It was a vulnerable micr... by ScanScor Admin
2 weeks ago MEIP – MEI Pharma Poised fo... – LITS (formerly MEIP) is not a viable biotech candidate f... by ScanScor Admin
2 weeks ago DRRX – Durect Set to Transf... – DURECT was acquired by Bausch Health, the merger closed b... by ScanScor Admin
3 weeks ago WVE – Wave Life Sciences: P... – WVE would have been wise to hire someone like myself to w... by ScanScor Admin
3 weeks ago WVE – Wave Life Sciences: P... – The biggest problem may not have been NDAPR at all. It ma... by ScanScor Admin

Recent Posts

NRXP – Summer FDA Ketamine Decision Could Reawaken NRXP Speculation
BIVI – BioVie’s next real test is the mid-2026 Parkinson’s readout
CNTB – Midyear Seabreeze data could decide CNTB’s next breakout
VRCA – VP-315 conference data could ignite VRCA’s next squeeze rally
SPRO – Spero Therapeutics Nears Potential Breakout with FDA Decision

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top